Breakthrough in Cancer Gene Therapy: Novel Liposomal Doxorubicin Formulation for Brain Tumor Treatment

Research conducted at King's College London has made significant strides in the field of cancer gene therapy, particularly in treating brain tumors. Investigators have developed a novel liposomal doxorubicin formulation, Talidox, designed to overcome the blood-brain barrier and deliver drugs directly to the brain. By combining Talidox with focused ultrasound and microbubble-mediated BBB transient opening, the team achieved a 14-fold increase in brain uptake of the formulation. This groundbreaking research highlights the potential of Talidox as a suitable choice for brain delivery and underscores the advantages of Positron Emission Tomography (PET) imaging for non-invasive, longitudinal quantification of drug delivery to the brain.

Key Takeaways:

• The blood-brain barrier (BBB) significantly hinders the treatment of central nervous system (CNS) disorders and brain tumors by restricting the entry of most therapeutic agents.
• Liposomal formulations, such as PEGylated liposomes, can be useful for brain drug delivery, but their large size often limits BBB penetration.
• The novel liposomal doxorubicin formulation, Talidox, has a smaller size (~36 nm) and increased blood circulation half-life (median reported half-life 96 h), making it a suitable choice for brain delivery.
• Focused ultrasound and microbubble-mediated BBB transient opening significantly increased brain uptake of Talidox, achieving a 14-fold higher accumulation compared to non-FUS controls.
• PET imaging revealed successful brain distribution of Talidox that correlated with experimental results, demonstrating the advantages of PET imaging as a modality for non-invasive, longitudinal quantification of drug delivery to the brain.
• This research has been peer-reviewed and published in the Journal of Controlled Release, with additional information available through King's College London.

Statistics:

• The brain uptake of Talidox increased 14-fold following focused ultrasound and microbubble-mediated BBB opening in mice.
• The median blood circulation half-life of Talidox was 96 hours.
• The size of Talidox is approximately 36 nanometers (nm) as determined by TEM.

Sources:

• NewsRx editors, "Studies Conducted at King's College London on Cancer Gene Therapy Recently Reported (PET imaging for non-invasive monitoring of 89Zr-Talidox delivery to the brain following focused ultrasound-mediated blood-brain barrier opening)".

Cancer Gene Therapy Week. September 15, 2025; p 158.

• Journal of Controlled Release. "PET imaging for non-invasive monitoring of 89Zr-Talidox delivery to the brain following focused ultrasound-mediated blood-brain barrier opening". Journal of Controlled Release, 2025:114183.